Coated or chewable Aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: Rationale and Design of the COATED-AIR Randomized Trial.

Authors

Behnood Bikdeli, Azita H Talasaz, Hooman Bakhshandeh, Mohammad Sadegh Hassanvand, Hessam Kakavand, Sepehr Jamalkhani, Sina Rashedi, Sara Tayyebi, Mohammadreza Babaei, Erfan Kohansal, Hamed Ghoshouni, Yasmin Mohtasham Kia, Mahsa Nikkhoo, Bahram Mohebbi, Maryam Aghakouchakzadeh, Saeed Alipour-Parsa, Armin Elahifar, Ehsan Khalilipur, Razieh Omidvar, Maryam Mehrpooya, Seyed Hashem Sezavar, David Jimenez, Luis Jara Palomares, Saeideh Mazloomzadeh, Naser Hadavand, Mehdi Ansari Dogaheh, Majid Maleki, Feridoun Noohi, Luis Ortega-Paz, Jayant K Raikhelkar, Philippe Gabriel Steg, Renato D Lopes, Raffaele De Caterina, Mehdi H Shishehbor, Loren Laine, Dominick J Angiolillo, Sanjay Rajagopalan, Ajay J Kirtane, Gregory Piazza, Gregory Y H Lip, Roxana Mehran, Harlan M Krumholz, Paul M Ridker, Parham Sadeghipour, COATED-AIR investigators

Published in

European heart journal. Cardiovascular pharmacotherapy. Sep 23, 2026. Epub Sep 23, 2026.

Abstract

Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular diseases (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials.
The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2x2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 hours of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrollment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric coated vs chewable aspirin 81mg daily, and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs usual care. The hybrid strategy includes 1. an educational flashcard, 2. real-time air quality alerts via cellular text messages, and recommendations to 2a. limit outdoor activity or 2b. to use a KN-95 facemask when outdoors, and 2c. to increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/nonfatal ischemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrollment was completed on 01/28/2026. Clinical follow-up and blinded event adjudications are ongoing.
COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.

PMID:
42772753
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.